Further results showed that combined treatment of bortezomib and 3-MA or siRNA knockdown of Atg7 resulted in a marked increase in caspase 3 activation compared with the tumor cells that were treated with bortezomib alone. This evidence concerns the gene ATG7 and neoplasm.